For US Healthcare Professionals Only
For US Healthcare Professionals Only
The resources on this page offer information and insights about Jakafi® (ruxolitinib) and treatment of patients with PV who have had an inadequate response to or are intolerant of HU. Be sure to check back regularly as new materials will be added as they become available.
Dr Claire Harrison discusses findings from the RESPONSE and MAJIC-PV studies, including data on the correlation between WBC control and thrombosis-free survival.
Dr Claire Harrison discusses results from the RESPONSE and MAJIC-PV studies, including data on Hct and thrombosis-free survival.
Hematologist-oncologist Dr Andrew Kuykendall shares how he manages progressive WBC counts and when it may be time to intervene with Jakafi.
Hematologist-oncologist Dr Andrew Kuykendall discusses maintaining strict Hct control and when it may be time to intervene with Jakafi.
Hematologist-oncologist Dr Andrew Kuykendall details how he uncovers symptoms in patients with PV, and when it may be time to intervene with Jakafi.
Hematologist-oncologist Dr Ruben Mesa discusses the importance of targeting optimal blood counts, assessing disease-related symptoms, and understanding when it may be the right time to intervene with Jakafi.
Hematology specialist Dr Harry Erba reviews the mechanism of action of Jakafi, a JAK1 and JAK2 inhibitor, highlighting how Jakafi works to inhibit overactive JAK pathway signaling. Dr Erba also discusses safety data from the RESPONSE trial, which compared Jakafi to BAT for patients with PV who were either intolerant of or had an inadequate response to HU.
Hematology specialist Dr Harry Erba discusses the appropriate dosing of Jakafi in patients with PV who have had an inadequate response to or are intolerant of HU. Dr Erba addresses the recommended starting dose, dose reductions based on hemoglobin levels and/or platelet counts, and dose modifications needed because of insufficient response in PV.
BAT=best available therapy; Hct=hematocrit; HU=hydroxyurea; JAK=janus kinase; PV=polycythemia vera; RESPONSE=Randomized study of Efficacy and Safety in POlycythemia vera with JAK iNhibitor ruxolitinib verSus bESt available care; WBC=white blood cell.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.